SGLT-2抑制剂对糖尿病肾病的保护作用的研究进展
| 作者: |
1赵珊珊,
2任毅,
2杨静
1 山西医科大学第一临床医学院，太原 030000 2 山西医科大学第一医院内分泌科，太原 030000 |
| 通讯: |
杨静
Email: yangjlm@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.05.024 |
| 基金: | 山西省卫生计生委科研课题(2017043)；山西省科技成果转化引导专项项目(201804D131044)。 |
摘要
糖尿病肾病(diabetic nephropathy，DN)是糖尿病严重的并发症之一，部分患者会进展为终末期肾病(end-stage renal disease，ESRD)，病死率明显高于不伴肾病的糖尿病患者。钠-葡萄糖转运蛋白2(sodium-glucose transporter 2，SGLT-2)抑制剂是一种新型降糖药物，目前研究发现，除降糖作用外还有减轻体重，改善血压，减少尿蛋白，降低血尿酸，改善肾小球超滤和氧化应激，抑制炎症和纤维化等作用，可以通过多种途径保护肾脏，有望用于预防及延缓DN的发生和发展。未来可以进一步探索SGLT-2抑制剂的肾保护机制，亦可以基于其肾保护作用扩展应用于非DN患者。
关键词：
钠-葡萄糖协同转运蛋白2抑制剂；糖尿病肾病；保护作用
Research progress on the protective effect of SGLT-2 inhibitors on diabetic nephropathy
CorrespondingAuthor: YANG Jing Email: yangjlm@126.com
DOI: 10.3978/j.issn.2095-6959.2021.05.024
Foundation: This woek was supported by Scientific Research Project of Shanxi Health and Family Planning Commission (2017043) and the Special Project for Transformation and Guidance of Scientific and Technological Achievements in Shanxi Province (01804D131044), China.
Abstract
Diabetic nephropathy (DN) is one of the serious complications of diabetes. Some patients will progress to end-stage renal disease (ESRD), and the mortality rate is significantly higher than that of diabetics without DN. Developed originally as glucose-lowering drugs by enhancing urinary glucose excretion, sodium-glucose transporter 2 (SGLT-2) inhibitors also lower many other renal risk factors such as body weight, blood pressure, albuminuria, uric acid and improve renal oxygenation, intra-renal inflammation thereby slowing the progression of kidney function decline. Future research can explore the mechanism of SGLT-2 inhibitors' protective effect on kidney, and its potential in the treatment of non-diabetic kidney disease.
Keywords：
sodium-glucose transporter 2 inhibitors; diabetic nephropathy; protective effect